



Atty. Dkt. No. 029318-0976

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ray W. WOOD et al.

Title: NANOPARTICULATE BECLOMETHASONE COMPOSITIONS

Appl. No.: 10/667,472

Filing Date: 09/23/2003

Examiner: Mina Haghighatian

Art Unit: 1616

TERMINAL DISCLAIMER FOR U.S. PATENT NO. 6,264,922

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Petitioner, Elan Pharma International Ltd., having its principal place of business at Treasury Building, Lower Grand Canal Street, Dublin 2, IRELAND, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application No. 10/667,472, filed on September 23, 2003, which is a continuation of U.S. Patent Application No. 09/577,489, filed on May 25, 2000, which is divisional of U.S. Patent Application No. 08/948,216, filed on October 9, 1997, now U.S. Patent No. 6,264,922, which is a continuation of U.S. Patent Application No. 08/589,681, filed on January 19, 1996, now abandoned, which is a continuation-in-part of U.S. Patent Application No. 08/394,103, filed on February 24, 1995. This application is owned by Elan Pharma International Ltd. by virtue of an Assignment from the inventors to Eastman Kodak Co. for Application No. 08/394,103 recorded on April 13, 1995, at Reel/Frame 007430/0713 (EXHIBIT 1); an Assignment from the inventors to Eastman Kodak Co. for Application No. 08/589,681 recorded on January 22, 1996, at Reel/Frame 007902/0485

01/03/2006 SZEWDIE1 00000099 10667472

02 FC:1814

130.00 DP

WASH_1511041.1

NOT AVAILABLE COPY

(EXHIBIT 2); an assignment from Eastman Kodak Co. to Particulate Prospects Corp. recorded on February 20, 1996, at Reel/Frame 007820/0153-0159 (EXHIBIT 3); an assignment from Particulate Prospects Corp. to NanoSystems LLC recorded on February 20, 1996, at Reel/Frame 007817/0273-0279 (EXHIBIT 4); an assignment from NanoSystems LLC to Elan Corporation plc recorded on May 5, 2000, at Reel/Frame 010797/0486-500 (EXHIBIT 5); and an assignment from Elan Corporation plc to Elan Pharma International Ltd. recorded on May 5, 2000, at Reel/Frame 010797/0501 in the United States Patent and Trademark Office (EXHIBIT 6).

Further, Petitioner represents that it is the owner of U.S. Patent No. 6,264,922 for "Nebulized Aerosols Containing Nanoparticle Dispersions," which issued on U.S. Patent Application No. 08/948,216, filed on October 9, 1997, which is a continuation of U.S. Patent Application No. 08/589,681, filed on January 19, 1996, now abandoned, which is a continuation-in-part of U.S. Patent Application No. 08/394,103, filed on February 24, 1995. This application is owned by Elan Pharma International Ltd. by virtue of an Assignment from the inventors to Eastman Kodak Co. for Application No. 08/394,103 recorded on April 13, 1995, at Reel/Frame 007430/0713 (EXHIBIT 1); an Assignment from the inventors to Eastman Kodak Co. for Application No. 08/589,681 recorded on January 22, 1996, at Reel/Frame 007902/0485 (EXHIBIT 2); an assignment from Eastman Kodak Co. to Particulate Prospects Corp. recorded on February 20, 1996, at Reel/Frame 007820/0153-0159 (EXHIBIT 3); an assignment from Particulate Prospects Corp. to NanoSystems LLC recorded on February 20, 1996, at Reel/Frame 007817/0273-0279 (EXHIBIT 4); an assignment from NanoSystems LLC to Elan Corporation plc recorded on May 5, 2000, at Reel/Frame 010797/0486-500 (EXHIBIT 5); and an assignment from Elan Corporation plc to Elan Pharma International Ltd. recorded on May 5, 2000, at Reel/Frame 010797/0501 in the United States Patent and Trademark Office (EXHIBIT 6).

Petitioner respectfully disagrees with the Examiner regarding the obviousness-type double patenting rejection given in the Office Action dated October 11, 2005. This Terminal Disclaimer is being filed for the sole purpose of advancing the prosecution of this case.

Petitioner hereby disclaims the terminal part of the term of any patent granted on the above-identified patent application which would extend beyond the full statutory term of U.S.

Patent No. 6,264,922. In addition, Petitioner hereby agrees that any patent so granted on the above-identified patent application shall be enforceable only for and during such period that the legal title to U.S. Patent No. 6,264,922 shall be the same as the legal title to any patent granted on the above-identified patent application, this agreement to run with any patent granted on the above identified patent application and to be binding upon the grantee, its successors, or assigns.

In making this disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above identified patent application, prior to the full statutory term of U.S. Patent No. 6,264,922 as defined in 35 U.S.C. §§ 154-156 and 173, in the event that U.S. Patent No. 6,264,922 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid in a final judgment by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 U.S.C. § 154, prior to the full statutory term of U.S. Patent No. 6,264,922 as defined in 35 U.S.C. §§ 154-156 and 173, except for the separation of legal title stated above.

Further, Petitioner does not disclaim any terminal part of a patent granted on the above identified patent application that would extend beyond the present termination of U.S. Patent No. 6,264,922, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§ 155, 155A, or 156, and without waiving Petitioner's right to extend the term of a patent granted on the above identified patent application to the extent provided by law.

The undersigned, being the Attorney of Record for the above identified patent application, and duly authorized to act on behalf of Petitioner, certifies that she has reviewed the Assignments attached as EXHIBITS 1-6, and to the best of her knowledge and belief, legal title to the above identified patent application and U.S. Patent No. 6,264,922 rests with Petitioner.

The undersigned declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing therefrom.

Respectfully submitted,

Date December 30, 2005

By Michele M. Simkin

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicants
Registration No. 34,717

EXHIBIT 1

Patent Assignment Abstract of Title

Total Assignments: 4

Application #: 08394103

Filing Dt: 02/24/1995

Patent #: NONE

Issue Dt:

PCT #: NONE

Publication #: NONE

Pub Dt:

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

Assignment: 1

Reel/Frame: 007430/0713 **Received:** **Recorded:** 04/13/1995 **Mailed:** 06/02/1995 **Pages:** 2

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: WOOD, RAY W.

Exec Dt: 04/03/1995

DECASTRO, LAN

Exec Dt: 04/03/1995

BOSCH, H.W.

Exec Dt: 04/03/1995

Assignee: EASTMAN KODAK COMPANY

ROCHESTER, NY 14650-2201

Correspondent: J. JEFFREY HAWLEY

EASTMAN KODAK COMPANY

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 2

Reel/Frame: 007817/0273

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/18/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: PARTICULATE PROPECTS CORP.

Exec Dt: 01/22/1996

Assignee: NANOSYSTEMS L.L.C.

COLLEGEVILLE, PENNSYLVANIA 19426

Correspondent: EASTMAN KODAK COMPANY,

MARY E. REED

PATENT LEGAL STAFF

ROCHESER, NY 14650-2201

Assignment: 3

Reel/Frame: 007820/0153

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/21/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: EASTMAN KODAK COMPANY

Exec Dt: 01/22/1996

Assignee: PARTICULATE PROSPECTS CORP.

ROCHESTER, NEW YORK 14650

Correspondent: EASTMAN KODAK COMPANY

MARY E. READ

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 4

Reel/Frame: 007987/0025 **Received:**
03/06/1996

Recorded:
02/20/1996

Mailed:
09/03/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: PARTICULATE PROSPECTS CORP.

Exec Dt: 01/22/1996

Assignee: NANOSYSTEMS L.L.C.

COLLEGEVILLE, PENNSYLVANIA 19426

Correspondent: EASTMAN KODAK COMPANY

MARY E. READ

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Search Results as of: 2/3/2004 11:40:21 A.M.

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 703-308-9723
Web interface last modified: Oct. 5, 2002

MAIL ROOM
APR 1995
1995
TRADEMARK
Date of Signature

I hereby certify that this correspondence is being deposited today with the United States Postal Service as first class mail, subject to the provisions of the United States Patent and Trademark Office, Washington, D.C. 20231.

Corrine V. Chorney
10 Apr 95

Docket 72048LJH

Form PTO 1595
1-97-08
MODIFIED 2-15-93

RECORDATION FORM COVER SHEET
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings → → →

(1) Name of conveying party(ies):
Assignor # 1: Ray W. Wood
Assignor # 2: Lan DeCastro
Assignor # 3: H. W. Bosch

(2) Name and address of receiving party(ies):
Name: Eastman Kodak Company City: Rochester State: NY Zip: 14650-2201

(3) Nature of Conveyance: ☒ Assignment ☐ Other:

Execution Date:
Assignor # 1: 03 April 1995
Assignor # 2: 03 April 1995
Assignor # 3: 03 April 1995

(4) Application number(s) or patent number(s): US 08/394,103
If this document is being filed together with a new application, the execution date of the application is the same as the execution date of the Assignment, unless stated as follows:

(5) Name and address of party to whom correspondence concerning document should be mailed:
Name: J. Jeffrey Hawley Address: Eastman Kodak Company, Patent Legal Staff
City: Rochester State: NY Zip: 14650-2201

(6) The total number of applications and patents involved is one (1) unless stated as follows:

(7) Total fee (37 CFR 1.21h): \$ ☐ Enclosed ☒ Authorized to be charged to deposit account

(8) Deposit account number: 05-0225
P 30079 04/19/95 08394103 DO NOT USE THIS SPACE 581 40.00CH

(9) Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Corrine V. Chorney
Name of Person Signing

Corrine V. Chorney
Signature

10 Apr 95
Date

(10) Total number of pages including cover sheet: 2

RECEIVED
95 MAY -1 AM 8:30
ASSIGNMENT BRANCH

REEL 1430 FRAME 113

93774903

ASSIGNMENT

Docket 72046JJH

For good and valuable consideration received, including salary or payment for the making of inventions, or employee benefits, I/we do hereby assign to Eastman Kodak Company, a New Jersey corporation having a principal place of business in Rochester, New York, its successors and assigns, the entire title, including priority rights in and to all of my/our inventions and improvements disclosed in an application for Letters Patent for **AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS** which was executed on the date shown below by:

Assignor # 1: Ray W. Wood	Date 4/3/95
Assignor # 2: Lan DeCastro	Date 4/3/95
Assignor # 3: H. William Bosch	Date 4/3/95

and [check one] ☒ about to be filed ☐ already filed as

in the United States Patent and Trademark Office, together with said application, and any divisional, continuation or reissue application thereof, applications corresponding thereto in whole or in part in all other countries, and title to Letters Patent and similar protective rights granted on said applications, as well as the right to claim any applicable priority rights arising from said applications under the terms of any applicable conventions, treaties, statutes or regulations, said applications to be filed and issued in the name of Eastman Kodak Company or its designee; and I/we agree to execute such documents as in the judgment of Eastman Kodak Company may be necessary to obtain any such patents and similar protective rights and maintain the title thereto in Eastman Kodak Company or its designee; and I/we further agree that, upon request, but without out-of-pocket expense to myself/ourselves, I/we shall furnish to Eastman Kodak Company or its designee any data, information, exhibits, memoranda, or other evidence in my/our possession relating to any of said inventions or improvements and shall testify in any ex parte or inter partes legal or administrative proceedings relating thereto; and I/we authorize and request issuance of all Letters Patent and similar protective rights that may be granted on any of said applications, to the extent that and in such manner as such issuance shall be requested by Eastman Kodak Company or its designee. This document shall be governed, construed and interpreted in all respects in accordance with the laws of the State of New York, USA.

<p>Signature of Assignor # 1</p> <p><i>Ray W. Wood</i></p> <p>Ray W. Wood</p> <p>Date: 4/3/95</p> <p>Witnessed: <i>H. William Bosch</i></p>	<p>Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650</p> <p>_____</p> <p>_____</p> <p>_____</p>
<p>Signature of Assignor # 2</p> <p><i>Lan DeCastro</i></p> <p>Lan DeCastro</p> <p>Date: 4/3/95</p> <p>Witnessed: <i>Ray W. Wood</i></p>	<p>Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650</p> <p>_____</p> <p>_____</p> <p>_____</p>
<p>Signature of Assignor # 3</p> <p><i>H. William Bosch</i></p> <p>H. William Bosch</p> <p>Date: April 3, 1995</p> <p>Witnessed: <i>Ray W. Wood</i></p>	<p>Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650</p> <p>_____</p> <p>_____</p> <p>_____</p>

REEL 7430 FRAME 14

RECORDED
PATENT & TRADE MARK OFFICE

APR 13 95

EXHIBIT 2

Patent Assignment Abstract of Title

Total Assignments: 1

Application #: 08589681

Filing Dt: 01/19/1996

Patent #: NONE

Issue Dt:

PCT #: NONE

Publication #: NONE

Pub Dt:

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

Assignment: 1

Reel/Frame: 007902/0485

Received:

04/26/1996

Recorded:

01/22/1996

Mailed:

07/14/1996

Pages: 2

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: WOOD, RAY W.

Exec Dt: 12/08/1995

DECASTRO, LAN

Exec Dt: 12/08/1995

BOSCH, H.W.

Exec Dt: 12/08/1995

Assignee: EASTMAN KODAK COMPANY

ROCHESTER, NEW YORK 14650

Correspondent: EASTMAN KODAK COMPANY

J. JEFFREY HAWLEY

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201


Search Results as of: 2/3/2004 11:39:57 A.M.

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 703-308-9723
Web interface last modified: Oct. 5, 2002



08/589681A117

04-26-1996



189189491

Express Mail Label No. EM46676602802

MKHQ 1/22/96

Docket 72046JH

Form PTO 1585
1-31-92

MODIFIED 2-15-93

RECORDATION FORM COVER SHEET
PATENTS ONLYU.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings → → →

1. Name of conveying party(ies):

Assignor # 1: Ray W. Wood
Assignor # 2: Lan DeCastro
Assignor # 3: H. W. Bosch

2. Name and address of receiving party(ies):

Name: Eastman Kodak Company City: Rochester State: NY Zip: 14650-2201

3. Nature of Conveyance: ☒ Assignment ☐ Other:

Execution Date:

Assignor # 1: 08 December 1995
Assignor # 2: 08 December 1995
Assignor # 3: 08 December 1995

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is the same as the execution date of the Assignment, unless stated as follows:

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: J. Jeffrey Hawley Address: Eastman Kodak Company, Patent Legal Staff
City: Rochester State: NY Zip: 14650-2201

6. The total number of applications and patents involved is one (1) unless stated as follows:

7. Total fee (37 CFR 1.21h): \$ ☐ Enclosed ☒ Authorized to be charged to deposit account

8. Deposit account number: 05-0225

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Corrine V. Chorney
Name of Person Signing

Signature

Date

Total number of pages including cover sheet 2

08/589681

Docket 72046AJJH

ASSIGNMENT

For good and valuable consideration received, including salary or payment for the making of inventions, or employee benefits, I/we do hereby assign to Eastman Kodak Company, a New Jersey corporation having a principal place of business in Rochester, New York, its successors and assigns, the entire right, title and interest, including priority rights, in and to all of my/our inventions and improvements disclosed in an application for patent for

AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

which is [check one]

- ☒ a non-provisional application for patent executed on the date(s) shown below by:
☐ a provisional application for patent by:
☐ an international application for patent by:

Assignor # 1: Ray W. Wood	Date <u>Dec 8, 1991</u>
Assignor # 2: Lan DeCastro	Date <u>Dec 8, 1991</u>
Assignor # 3: H. W. Bosch	Date <u>Dec 8, 1991</u>

and [check one] ☒ about to be filed ☐ already filed as

in the United States Patent and Trademark Office, together with said application, and any corresponding or counterpart provisional or non-provisional application, and any divisional, continuation, substitute, reissue, re-examination application thereof, and any applications, including international applications, corresponding or being a counterpart thereto in whole or in part in the United States and all other countries. I/We also do hereby assign to Eastman Kodak Company the entire right, title and interest in and to Letters Patent and similar protective rights granted on any of these applications, as well as the right to claim any applicable priority rights arising from any of these applications under the terms of any applicable conventions, treaties, statutes or regulations. I/We agree that any of these applications, at Eastman Kodak Company's sole discretion, may be filed and issued in the name of Eastman Kodak Company or its designee. I/We agree to execute such documents which in the judgment of Eastman Kodak Company may be necessary to obtain any such patents and similar protective rights and to maintain the title thereto in Eastman Kodak Company or its designee. I/We further agree that, upon request, but without out-of-pocket expense to myself/ourselves, I/we shall furnish to Eastman Kodak Company or its designee any data, information, exhibits, memoranda, or other evidence in my/our possession relating to any of said inventions or improvements and shall testify in any ex parte or inter partes legal or administrative proceedings relating thereto. I/We authorize and request issuance of all Letters Patent and similar protective rights that may be granted on any of these applications, to the extent that and in such manner as such issuance shall be requested by Eastman Kodak Company or its designee. This document shall be governed, construed and interpreted in all respects in accordance with the laws of the State of New York, USA.

Signature of Assignor # 1 <u>Ray W. Wood</u> Date: <u>Dec 8, 1991</u> Witnessed: <u>[Signature]</u>	Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650 <u>1408 Crystal Valley Drive</u> <u>Ambler, PA 19002</u>
Signature of Assignor # 2 <u>Lan DeCastro</u> Date: <u>Dec 8, 1991</u> Witnessed: <u>[Signature]</u>	Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650 <u>1408 Crystal Valley Drive</u> <u>Ambler, PA 19002</u>
Signature of Assignor # 3 <u>H. W. Bosch</u> Date: <u>Dec 8, 1991</u> Witnessed: <u>[Signature]</u>	Witness Address, if other than Eastman Kodak Company, Rochester, NY 14650 <u>1408 Crystal Valley Drive</u> <u>Ambler, PA 19002</u>

RECORDED: 01/22/1996

Page 1 of 1

PATENT

REEL: 7902 FRAME: 0486

EXHIBIT 3

Patent Assignment Abstract of Title

Total Assignments: 4

Application #: 08394103

Filing Dt: 02/24/1995

Patent #: NONE

Issue Dt:

PCT #: NONE

Publication #: NONE

Pub Dt:

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

Assignment: 1

Reel/Frame: 007430/0713 Received: Recorded: 04/13/1995 Mailed: 06/02/1995 Pages: 2

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: WOOD, RAY W.

Exec Dt: 04/03/1995

DECASTRO, LAN

Exec Dt: 04/03/1995

BOSCH, H.W.

Exec Dt: 04/03/1995

Assignee: EASTMAN KODAK COMPANY

ROCHESTER, NY 14650-2201

Correspondent: J. JEFFREY HAWLEY

EASTMAN KODAK COMPANY

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 2

Reel/Frame: 007817/0273

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/18/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: PARTICULATE PROPECTS CORP.

Exec Dt: 01/22/1996

Assignee: NANOSYSTEMS L.L.C.

COLLEGEVILLE, PENNSYLVANIA 19426

Correspondent: EASTMAN KODAK COMPANY,

MARY E. REED

PATENT LEGAL STAFF

ROCHESER, NY 14650-2201

Assignment: 3

Reel/Frame: 007820/0153

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/21/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: EASTMAN KODAK COMPANY

Exec Dt: 01/22/1996

Assignee: PARTICULATE PROSPECTS CORP.

ROCHESTER, NEW YORK 14650

Correspondent: EASTMAN KODAK COMPANY

MARY E. READ

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 4

Reel/Frame: 007987/0025 **Received:** 03/06/1996 **Recorded:** 02/20/1996 **Mailed:** 09/03/1996 **Pages:** 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: PARTICULATE PROSPECTS CORP.

Exec Dt: 01/22/1996

Assignee: NANOSYSTEMS L.L.C.

COLLEGEVILLE, PENNSYLVANIA 19426

Correspondent: EASTMAN KODAK COMPANY
MARY E. READ
PATENT LEGAL STAFF
ROCHESTER, NY 14650-2201

Search Results as of: 2/3/2004 11:40:21 A.M.

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 703-308-9723
Web interface last modified: Oct. 1, 2002

2-20-96

03-06-1996

Record 1st

Form PTO 1588
1-31-82
MODIFIED 2-18-93RECORDATION FORM C
PATENTS-01

100144279

1 PPC

DEPT OF COMMERCE
and Trademark Office

Tab settings → → → t t

1. Name of conveying party(ies):

EASTMAN KODAK COMPANY

FEB 20 1996

RECEIPT ACTING DIV.

2. Name and address of receiving party(ies):

Name: PARTICULATE PROSPECTS CORP. City: Rochester State: New York Zip: 14850

3. Nature of Conveyance: ☒ Assignment ☐ Other.Execution Date: January 22, 1996
(Effective Date: 21 December 1995)4. Application number(s) or patent number(s): See Attached Assignment - Application
(If this document is being filed together with a new application, the execution date of the application is the same as the execution date of the Assignment, unless stated as follows:

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Mary E. Read Address: Eastman Kodak Company, Patent Legal Staff
City: Rochester State: New York Zip: 14850-2201

6. The total number of applications and patents involved is one (1) unless stated as follows: 54

7. Total fee (37 CFR 1.21h): \$2,160 ☐ Enclosed ☒ Authorized to be charged to deposit account

8. Deposit account number: 05-0225

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

HG11296 03/04/96 08180827 05-0225 110 581 2,160.00CH

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mary E. Read

Name of Person Signing

Signature

February 16 1996

Date

Total number of pages including cover sheet: 7

PATENT
REEL: 7820 FRAME: 0153

JAN 05, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM EASTMAN KODAK
 TO PARTICULATE PROSPECTS CORPORATION
 APPLICATIONS

PAGE 54

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
66111	BRUNO, J - ET AL -	08/180,827 12JAN94	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
70475	CZEKAI, DA - ET AL -	08/249,787 25MAY94	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
68558	BACON, ER - ET AL -	08/265,550 24JUN94	NANOPARTICULATE DIAGNOSTIC DIATRIZOXY ESTER X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
69226	BACON, ER - ET AL -	08/265,403 24JUN94	ALPHA-TCYCLOALKYL, ARYL AND ARALKYL SUBSTITUTED POLYIODINATED ACRYLOXY ESTERS
70545	BACON, ER - ET AL -	08/265,590 24JUN94	2,4,6-TRI(000-5-SUBSTITUTED-AMINO-ISOPTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTIC IMAGING
68175	WONG, S	08/267,082 28JUN94	BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS
61684	MCINTIRE, G - ET AL -	08/312,725 27SEP94	CONTROLLED PRECIPITATION OF PARTICULATE DIAGNOSTIC IMAGING CONTRAST AGENTS
61894	LIVERSIDGE, G - ET AL -	08/345,267 28DEC94	SURFACE MODIFIED ANTICANCER NANOPARTICLES
71869	BAGCHI, P - ET AL -	08/370,935 10JAN95	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS
71870	BAGCHI, P - ET AL -	08/370,998 10JAN95	CO-MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS WITH CRYSTAL GROWTH MODIFIERS
71871	BAGCHI, P - ET AL -	08/370,928 10JAN95	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS USING SURFACE ACTIVE MATERIAL DERIVED FROM SIMILAR PHARMACEUTICAL AGENTS
71872	BAGCHI, P - ET AL -	08/370,934 10JAN95	MICROPRECIPITATION OF MICRONANOPARTICULATE PHARMACEUTICAL AGENTS
67097	WONG, SM. J. - ET AL -	08/378,022 24JAN95	SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS

PATENT
 REEL: 7820 FRAME: 0154

JAN 05, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM EASTMAN KODAK
 TO PARTICULATE PROSPECTS CORPORATION
 APPLICATIONS

PAGE 55

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
71758	EICKHOFF, WM - ET AL -	08/384,057 06FEB95	FORMULATIONS OF COMPOUNDS AS NANOPARTICLE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
70130	SIRIAMNI, J	08/384,992 07FEB95	HYDRODYNAMICALLY OPTIMIZED VIALS FOR NANOPARTICULATE SUSPENSIONS OF DRUGS
64730	WONG, S-M	08/385,502 08FEB95	DUAL PURPOSED DIAGNOSTIC/THERAPEUTIC AGENT
71762	RUDY, SB - ET AL -	08/385,531 08FEB95	ISOLATION OF ULTRA SMALL PARTICLES
69468	DECASTRO, L	08/386,028 09FEB95	A METHOD OF PREPARING STABLE DRUG NANOPARTICLES
70429	WONG, SUI-MING	08/386,026 09FEB95	SUGAR BASE SURFACTANT FOR NANOCRYSTALS
70433	EICKHOFF, WM - ET AL -	08/386,614 09FEB95	NANOPARTICULATE NSAID POSITIONS
69470	KELLY, OI	08/386,788 10FEB95	NANOPARTICULATE DIAGNOSTIC DIMERS AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
70903	FRANSON, WM - ET AL -	08/386,790 10FEB95	MILLED NAPROXEN WITH HYDROXYPROPYL CELLULOSE AS A DISPERSION STABILIZER
66793	DESIGENO, MA - ET AL -	08/387,651 13FEB95	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
71758	EICKHOFF, WM - ET AL -	08/388,088 14FEB95	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
69883	RUDY, S - ET AL -	08/388,878 15FEB95	SITE-SPECIFIC ADHESION WITHIN THE GI TRACT USING NANOPARTICLES STABILIZED BY HIGH MOLECULAR WEIGHT T LINEAR POLY (ETHYLENE OXIDE) POLYMERS **SEE FM**
71707	RUDY, SB - ET AL -	08/393,648 24FEB95	NANOPARTICLES CONTAINING THE R(-) ENANTIOMER OF ISUPROFEN

PATENT
 REEL: 7820 FRAME: 0153

JAN 05, 1996

APPENDIX - A
ASSIGNMENT OF CASES FROM EASTMAN KODAK
TO PARTICULATE PROSPECTS CORPORATION
APPLICATIONS

PAGE 56

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
71818	WONG, BN - ET AL -	08/393,972 24FEB95	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
72046	WOOD, R	08/394,103 24FEB95	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
72203	WIEDMANN, TS - ET AL -	08/393,973 24FEB95	AEROSOLS CONTAINING BECLOMETHAZONE NANOPARTICLE DISPERSIONS
66540	ILLIG, C	08/401,397 09MAR95	NANOPARTICULATE DIAGNOSTIC MIXED CARBOXYLIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
61894	LIVERSIDGE, G - ET AL -	08/402,662 13MAR95	SURFACE MODIFIED NSAD PARTICLES
69147	OSIFO, IK	08/440,794 15MAY95	NANOPARTICULATE IODIPAMIDE DERIVATIVES FOR USE AS X-RAY CONTRAST AGENTS
70429	WONG, SUI-MING	08/444,796 19MAY95	SUGAR BASE SURFACTANT FOR NANOCRYSTALS
70001	SINGH, B	08/447,133 22MAY95	DIAGNOSTIC IMAGING X-RAY CONTRAST AGENTS
70537	SING, B	08/447,132 22MAY95	3,5-BIS-ALKANOYL AMINO-2,4,6-TRIIODOBENZYL ESTERS
69802	CZEKAI, DA - ET AL -	08/491,539 15JUN95	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
70432	WONG, SUI-MING	60/001,985 26JUL95	METHACRYLATE BACKBONE SURFACTANTS IN NANOPARTICULATE FORMULATIONS
70321	ROBINSON, S - ET AL -	60/002,088 10AUG95	NOVEL 3-AMIDO-TRIIODOPHENYL ESTERS AS X-RAY CONTRAST AGENTS
70323	BACON, ER - ET AL -	60/002,103 10AUG95	TRIODOALKYLPHENYL ESTERS AS NOVEL X-RAY CONTRAST AGENTS

PATENT
 REEL: 7820 FRAME: 0156

JAN 03, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM EASTMAN KODAK
 TO PARTICULATE PROSPECTS CORPORATION
 APPLICATIONS

PAGE 59

US 813

DOCKET	INVENTOR(S)	APPL/NO/DATE	TITLE
67099	LIVERSIDGE, G - ET AL -	08/366,841 30DEC94	IMPROVED FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS AND ORAL GASTROINTESTINAL THERAPEUTIC AGENTS
71819	RIDDY, SS - ET AL -	08/366,518 30DEC94	FORMULATIONS OF ORAL GASTROINTESTINAL THERAPEUTIC AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
69703	RIDDY, SS - ET AL -	08/366,027 09FEB95	NOVEL BARIUM SALT FORMULATIONS STABILIZED BY NON- IONIC AND ANIONIC STABILIZERS
70779	MARCERA, DM - ET AL -	08/388,077 14FEB95	PROCESS OF PREPARING LYMPHOGRAPHY CONTRAST AGENTS
72101	BOSCH, HW - ET AL -	08/388,092 14FEB95	PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES
72102	SHANSON, JR - ET AL -	08/388,099 14FEB95	PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES
61347	LIVERSIDGE, G - ET AL -	08/388,857 03APR95	ANTACID COMPOSITION AND METHOD OF PRODUCTION
72953	JONES, AM - ET AL -	60/004,072 21SEP95	NANOPARTICULATE PHENYTOIN FORMULATION
72993	DECARAVILLA, L - ET AL -	60/004,488 29SEP95	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
72248	BOSCH, HW - ET AL -	60/002,102 10AUG95	NANOPARTICULATE IODIPAMIDE FORMULATIONS FOR MEDICAL X-RAY IMAGE ENHANCEMENT
66540	ILLIG, C	08/524,145 22AUG95	NANOPARTICULATE DIAGNOSTIC MIXED CARBONIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
64616	BACON, E - ET AL -	08/558,925 13NOV95	IODINATED WETTING AGENTS
61684	McIntire, G. et al. (Rule 62 Cont. of US08/312,725)	08/588,277 18JAN95	CONTROLLED PRECIPITATION OF PARTICULATE DIAGNOSTIC IMAGING CONTRAST AGENTS
70545	Bacon, ER et al. (Rule 62 Cont. of US08/265,590)	08/586,363 16JAN95	2,4,6-TRIIODO-5 SUBSTITUTED-AMINO- ISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTIC IMAGING
72046	Wood et al. (Continuation-in-Part of US 08/394,193 filed 24 February 1995)	19JAN95	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

PATENT

REEL: 7820 FRAME: 0157

ASSIGNMENT OF INVENTION

THIS Assignment is effective the 21 day of December, 1995,
BETWEEN Eastman Kodak Company, of 343 State Street, Rochester,
New York 14650, United States of America, a corporation of the State of New
Jersey (hereinafter the "Assignor"), who is the owner of the entire title in the
United States applications set forth in Appendix A and in the inventions
covered by said applications; and

Particulate Prospects Corp., of 343 State Street, Rochester, New York
14650, United States of America, a corporation of the State of Delaware
(hereinafter the "Assignee"), who wants to acquire the entire title of Assignor
in the aforesaid applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of
which is hereby acknowledged, Assignor does hereby assign unto Assignee
its entire title in and to said inventions covered by said applications, and all
corresponding patents and patent applications in countries other than the
United States, and all reissues, divisions and extensions thereof and to any
Letters Patent which have or may issue based thereon, all of which are
encompassed herein by the term "Patents", including all claims for damage
for past infringement thereof; the same to be held and enjoyed by Assignee,
its successors, and assigns, as fully and entirely as the same would have
been held and enjoyed by Assignor had this assignment and sale not been
made.

Assignor also agrees that it will, at Assignee's request, render such
lawful cooperation and assistance as may be necessary for the proper
maintenance and enforcement of said patents, provided, however, that
Assignor may condition its compliance with such a request on Assignee's
agreement to pay Assignor reasonable out-of-pocket expenses in connection
therewith.

This document shall be construed, interpreted and applied in
accordance with the laws of the State of New York.

IN WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this
22 day of January, 1996.

Eastman Kodak Company

By Peter Giles *AMZ*

Peter Giles

Vice-President

Director of Commercial Affairs

(Corporate Seal)

Witnessed by: Mary T. Reed

IN WITNESS WHEREOF, I have hereunto set hand and seal this
22 day of January, 1996.

Particulate Prospects Corp.

By Douglas A. Mabon

Douglas A. Mabon

President

(Corporate Seal)

Witnessed by: Mary T. Reed

RECORDED: 02/20/1996

PATENT
REEL: 7820 FRAME: 0159

EXHIBIT 4

Patent Assignment Abstract of Title

Total Assignments: 4

Application #: 08394103

Filing Dt: 02/24/1995

Patent #: NONE

Issue Dt:

PCT #: NONE

Publication #: NONE

Pub Dt:

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

Assignment: 1

Reel/Frame: 007430/0713 **Received:** **Recorded:** 04/13/1995 **Mailed:** 06/02/1995 **Pages:** 2

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: WOOD, RAY W.

Exec Dt: 04/03/1995

DECASTRO, LAN

Exec Dt: 04/03/1995

BOSCH, H.W.

Exec Dt: 04/03/1995

Assignee: EASTMAN KODAK COMPANY

ROCHESTER, NY 14650-2201

Correspondent: J. JEFFREY HAWLEY

EASTMAN KODAK COMPANY

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 2

Reel/Frame: 007817/0273

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/18/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: PARTICULATE PROPECTS CORP.

Exec Dt: 01/22/1996

Assignee: NANOSYSTEMS L.L.C.

COLLEGEVILLE, PENNSYLVANIA 19426

Correspondent: EASTMAN KODAK COMPANY,

MARY E. REED

PATENT LEGAL STAFF

ROCHESER, NY 14650-2201

Assignment: 3

Reel/Frame: 007820/0153

Received:
03/06/1996

Recorded:
02/20/1996

Mailed:
05/21/1996

Pages: 7

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: EASTMAN KODAK COMPANY

Exec Dt: 01/22/1996

Assignee: PARTICULATE PROSPECTS CORP.

ROCHESTER, NEW YORK 14650

Correspondent: EASTMAN KODAK COMPANY

MARY E. READ

PATENT LEGAL STAFF

ROCHESTER, NY 14650-2201

Assignment: 4

2-20-96

03-06-1996

Record 2nd
of NANOForm PTO 1580
1-31-92
MODIFIED 2-15-93

RECORDATION FORM

FEB 2 PATENTS



100144278

DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab markings → → → t

t

1. Name of conveying party(ies):

PARTICULATE PROSPECTS CORP.

2. Name and address of receiving party(ies):

Name: NANOSYSTEMS L.L.C. City: Collegeville State: Pennsylvania Zip: 19426

3. Nature of Conveyance: ☒ Assignment ☐ Other:Execution Date: January 22, 1996 and February 8, 1996
(Effective date: December 21, 1995)

4. Application number(s) or patent number(s): (See Attached Assignment - Applications)

If this document is being filed together with a new application, the execution date of the application is the same as the execution date of the Assignment, unless stated as follows:

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Mary E. Read Address: Eastman Kodak Company, Patent Legal Staff
City: Rochester State: New York Zip: 14650-2201

6. The total number of applications and patents involved is one (1) unless stated as follows: 54

7. Total fee (37 CFR 1.21h): \$2,160 ☐ Enclosed ☒ Authorized to be charged to deposit account

8. Deposit account number: 05-0225

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mary E. Read

Name of Person Signing

Signature

February 16, 1996

Date

Total number of pages including cover sheet: 78

HG11297 03/04/96 08180827

05-0225 110 581 2,160.00CH

PATENT

REEL: 7817 FRAME: 0273

JAN 05, 1996

APPENDIX - A
ASSIGNMENT OF CASES FROM PARTICULATE PROSPECTS CORPORATION
TO NANO SYSTEMS L. L. C.
APPLICATIONS

PAGE 54

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
66111	BRUNO, J - ET AL -	08/180,827 12JAN94	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
70475	CZEKAJ, DA - ET AL -	08/249,787 25MAY94	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
68558	BACON, ER - ET AL -	08/265,550 24JUN94	NANOPARTICULATE DIAGNOSTIC DIATRIZOXY ESTER X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
69226	BACON, ER - ET AL -	08/265,603 24JUN94	ALPHA-XYCLOALKYL, ARYL AND ARALKYL SUBSTITUTED POLYIODINATED AROYLOXY ESTERS
70545	BACON, ER - ET AL -	08/265,590 24JUN94	2,4,6-TRIICDO-5-SUBSTITUTED-AMINO-ISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTIC IMAGING
68175	WONG, S	08/267,082 28JUN94	BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS
61684	MCINTIRE, G - ET AL -	08/312,725 27SEP94	CONTROLLED PRECIPITATION OF PARTICULATE DIAGNOSTIC IMAGING CONTRAST AGENTS
61894	LIVERSIDGE, G - ET AL -	08/345,267 28DEC94	SURFACE MODIFIED ANTICANCER NANOPARTICLES
71869	BAGCHI, P - ET AL -	08/370,955 10JAN95	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS
71870	BAGCHI, P - ET AL -	08/370,998 10JAN95	CO-MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS WITH CRYSTAL GROWTH MODIFIERS
71871	BAGCHI, P - ET AL -	08/370,928 10JAN95	MICROPRECIPITATION OF NANOPARTICULATE PHARMACEUTICAL AGENTS USING SURFACE ACTIVE MATERIAL DERIVED FROM SIMILAR PHARMACEUTICAL AGENTS
71872	BAGCHI, P - ET AL -	08/370,936 10JAN95	MICROPRECIPITATION OF MICRONANOPARTICULATE PHARMACEUTICAL AGENTS
67097	WONG, SM.J. - ET AL -	08/378,022 24JAN95	SULFATED NONIONIC BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOPARTICLE COMPOSITIONS

JAN 03, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM PARTICULATE PROSPECTS CORPORATION
 TO NANO SYSTEMS L. L. C.
 APPLICATIONS

PAGE 55

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
71758	EICKHOFF, WM - ET AL -	08/384,057 06FEB95	FORMULATIONS OF COMPOUNDS AS NANOPARTICLE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
70130	SIRIANNI, J	08/384,992 07FEB95	HYDRODYNAMICALLY OPTIMIZED VIALS FOR NANOPARTICULATE SUSPENSIONS OF DRUGS
64730	WONG, S-M	08/385,502 08FEB95	DUAL PURPOSED DIAGNOSTIC/THERAPEUTIC AGENT
71762	RUDDY, SB - ET AL -	08/385,531 08FEB95	ISOLATION OF ULTRA SMALL PARTICLES
69468	DECASTRO, L	08/386,028 09FEB95	A METHOD OF PREPARING STABLE DRUG NANOPARTICLES
70429	WONG, SUI-MING	08/386,026 09FEB95	SUGAR BASE SURFACTANT FOR NANOCRYSTALS
70433	EICKHOFF, WM - ET AL -	08/385,614 09FEB95	NANOPARTICULATE NSAID POSITIONS
69470	KELLY, OI	08/386,788 10FEB95	NANOPARTICULATE DIAGNOSTIC DIMERS AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
70903	FRANSON, WM - ET AL -	08/386,790 10FEB95	MILLED NAPROXEN WITH HYDROXYPROPYL CELLULOSE AS A DISPERSION STABILIZER
66793	DESIENO, MA - ET AL -	08/387,651 13FEB95	REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS
71758	EICKHOFF, WM - ET AL -	08/388,088 14FEB95	FORMULATIONS OF COMPOUNDS AS NANOPARTICULATE DISPERSIONS IN DIGESTIBLE OILS OR FATTY ACIDS
69683	RUDDY, S - ET AL -	08/388,878 15FEB95	SITE-SPECIFIC ADHESION WITHIN THE GI TRACT USING NANOPARTICLES STABILIZED BY HIGH MOLECULAR WEIGHT T LINEAR POLY (ETHYLENE OXIDE) POLYMERS **SEE FN**
71707	RUDDY, SB - ET AL -	08/393,648 24FEB95	NANOPARTICLES CONTAINING THE R(-) ENANTIOMER OF IBUPROFEN

JAN 03, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM PARTICULATE PROSPECTS CORPORATION
 TO NANO SYSTEMS L. L. C.
 APPLICATIONS

PAGE 56

US

DOCKET	INVENTOR(S)	APPLNO/DATE	TITLE
71818	WONG, SH - ET AL -	08/393,972 26FEB95	POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES
72046	WOOD, R	08/394,103 26FEB95	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS
72203	WIEDMANN, TS - ET AL -	08/393,973 26FEB95	AEROSOLS CONTAINING BECLONETHAZONE NANOPARTICLE DISPERSIONS
66540	ILLIG, C	08/401,397 09MAR95	NANOPARTICULATE DIAGNOSTIC MIXED CARBOXYLIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
61894	LIVERIDGE, G - ET AL -	08/402,662 13MAR95	SURFACE MODIFIED NSAID PARTICLES
69147	OSIFO, IK	08/440,794 15MAY95	NANOPARTICULATE IODIPAMIDE DERIVATIVES FOR USE AS X-RAY CONTRAST AGENTS
70429	WONG, SUI-MING	08/444,796 19MAY95	SUGAR BASE SURFACTANT FOR NANOCRYSTALS
70001	SINGH, B	08/447,133 22MAY95	DIAGNOSTIC IMAGING X-RAY CONTRAST AGENTS
70537	SING, B	08/447,132 22MAY95	3,5-BIS-ALKANOYL AMINO-2,4,6-TRIIODOBENZYL ESTERS
69602	CZEKAI, DA - ET AL -	08/491,539 15JUN95	METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES
70432	WONG, SUI-MING	60/001,985 26JUL95	METHACRYLATE BACKBONE SURFACTANTS IN NANOPARTICULATE FORMULATIONS
70321	ROBINSON, S - ET AL -	60/002,088 10AUG95	NOVEL 3-AMIDO-TRIIODOPHENYL ESTERS AS X-RAY CONTRAST AGENTS
70323	BACON, ER - ET AL -	60/002,103 10AUG95	TRIODOALKYLPHENYL ESTERS AS NOVEL X-RAY CONTRAST AGENTS

PATENT
 REEL: 7817 FRAME: 0276

JAN 05, 1996

APPENDIX - A
 ASSIGNMENT OF CASES FROM PARTICULATE PROSPECTS CORPORATION
 TO NANO SYSTEMS L. L. C.
 APPLICATIONS

PAGE 57

US RJR

DOCKET	INVENTOR(S)	APPL/NO/DATE	TITLE
67099	LIVERSIDGE, G - ET AL -	08/366,841 30DEC94	IMPROVED FORMULATIONS OF ORAL GASTROINTESTINAL DIAGNOSTIC X-RAY CONTRAST AGENTS AND ORAL GASTROINTESTINAL THERAPEUTIC AGENTS
71819	NUDDY, SB - ET AL -	08/366,518 30DEC94	FORMULATIONS OF ORAL GASTROINTESTINAL THERAPEUTIC AGENTS IN COMBINATION WITH PHARMACEUTICALLY ACCEPTABLE CLAYS
69703	NUDDY, SB - ET AL -	08/386,027 09FEB95	NOVEL BARIUM SALT FORMULATIONS STABILIZED BY NON- IONIC AND ANIONIC STABILIZERS
70779	MARCERA, DM - ET AL -	08/388,097 14FEB95	PROCESS OF PREPARING LYMPHOGRAPHY CONTRAST AGENTS
72101	BOSCH, HW - ET AL -	08/388,092 14FEB95	PROCESS OF PREPARING THERAPEUTIC COMPOSITIONS CONTAINING NANOPARTICLES
72102	SWANSON, JR - ET AL -	08/388,099 14FEB95	PROCESS OF PREPARING X-RAY CONTRAST COMPOSITIONS CONTAINING NANOPARTICLES
61347	LIVERSIDGE, G - ET AL -	08/388,857 03APR95	ANTACID COMPOSITION AND METHOD OF PRODUCTION
72953	JONES, AW - ET AL -	60/004,072 21SEP95	NANOPARTICULATE PHENYTOIN FORMULATION
72993	DEBARAVILLA, L - ET AL -	60/004,488 29SEP95	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
72248	BOSCH, HW - ET AL -	60/002,102 10AUG95	NANOPARTICULATE IODIPAMIDE FORMULATIONS FOR MEDICAL X-RAY IMAGE ENHANCEMENT
66540	ILLIG, C	08/524,145 22AUG95	NANOPARTICULATE DIAGNOSTIC MIXED CARBONIC ANHYDRIDES AS X-RAY CONTRAST AGENTS FOR BLOOD POOL AND LYMPHATIC SYSTEM IMAGING
64616	BACON, E - ET AL -	08/558,925 13NOV95	IODINATED WETTING AGENTS
61684	McIntire, G. et al. (Rule 62 Cont. of US08/312,725)	08/588,277 18JAN96	CONTROLLED PRECIPITATION OF PARTICULATE DIAGNOSTIC IMAGING CONTRAST AGENTS
70545	Bacon, ER et al. (Rule 62 Cont. of US08/265,590)	08/586,363 16JAN96	2,4,6-TRIIODO-5-SUBSTITUTED-AMINO- ISOPHTHALATE ESTERS USEFUL AS X-RAY CONTRAST AGENTS FOR MEDICAL DIAGNOSTIC IMAGING
72046	Wood et al. (Continuation-in-Part of US 08/394,103 filed 24 February 1995)	19JAN96	AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS

PATENT

REEL: 7817 FRAME: 0277

ASSIGNMENT OF INVENTION

**THIS Assignment is effective the 21 day of December, 1995,
BETWEEN Particulate Prospects Corp., of 343 State Street,
Rochester, New York 14650, United States of America, a corporation of the
State of Delaware (hereinafter the "Assignor"), who is the owner of the entire
title in the United States applications set forth in Appendix A and in the
inventions covered by said applications; and**

**NanoSystems L.L.C., of 1250 South Collegeville Road, Collegeville,
Pennsylvania 19426, USA, a corporation of the State of Delaware (a Limited
Liability Company) (hereinafter the "Assignee"), who wants to acquire the
entire title of Assignor in the aforesaid applications and the inventions
covered thereby.**

**THEREFORE, for good and valuable consideration, the receipt of
which is hereby acknowledged, Assignor does hereby assign unto Assignee
its entire title in and to said inventions covered by said applications, and all
corresponding patents and patent applications in countries other than the
United States, and all reissues, divisions and extensions thereof and to any
Letters Patent which have or may issue based thereon, all of which are
encompassed herein by the term "Patents", including all claims for damage
for past infringement thereof; the same to be held and enjoyed by Assignee,
its successors, and assigns, as fully and entirely as the same would have
been held and enjoyed by Assignor had this assignment and sale not been
made.**

**Assignor also agrees that it will, at Assignee's request, render such
lawful cooperation and assistance as may be necessary for the proper
maintenance and enforcement of said patents, provided, however, that
Assignor may condition its compliance with such a request on Assignee's
agreement to pay Assignor reasonable out-of-pocket expenses in connection
therewith.**

**This document shall be construed, interpreted and applied in
accordance with the laws of the State of New York.**

IN WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this
22 day of January, 1996.

Particulate Prospects Corp.

By Douglas A. Mabon

Douglas A. Mabon
President

(Corporate Seal)

Witnessed by: Mary E. Reed

IN WITNESS WHEREOF, I have hereunto set hand and seal this
8 day of February, 1996,

NanoSystems L.L.C.

By Larry A. Sternson

Larry A. Sternson
President

(Corporate Seal)

Witnessed by: Gilbert W. Ruelman

EXHIBIT 5

Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2

Patent #: 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS

Assignment: 1

Reel/Frame: 010797/0486

Recorded: 05/05/2000

Pages: 15

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: NANOSYSTEMS, L.L.C.

Exec Dt: 10/01/1998

Assignee: ELAN CORPORATION, PLC
LINCOLN HOUSE, LINCOLN PLACE
DUBLIN 2, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8696

Assignment: 2

Reel/Frame: 010797/0501

Recorded: 05/05/2000

Pages: 17

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ELAN CORPORATION, PLC

Exec Dt: 10/01/1998

Assignee: ELAN PHARMA INTERNATIONAL LIMITED
WIL HOUSE, SHANNON BUSINESS PARK
SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-8696

Search Results as of: 02/03/2004 10:51 AM

D/4

Atty. Dkt. No. 029318/0440

FORM PTO-1585 (modified)

(Rev. 9-93)

REC

05-23-2000



HEET

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

5500

101364077

To the Commissioner of Patents and Trademarks. Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

NanoSystems, L.L.C.



Additional conveying party(ies)

NO

2. Name and address of receiving party(ies):

Elan Corporation, PLC
Lincoln House, Lincoln Place
Dublin 2, IRELAND

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer
POLNY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
P.O. Box 25696
Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. 5.3.41): \$40.00

☒ Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05/22/2000 JUNE 22 000007Z 00340216

DO NOT USE THIS SPACE

01 F1581

44.00

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

Michele M. Schafer

May 5, 2000

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 15



ASSET PURCHASE AGREEMENT

by and between

**NANOSYSTEMS L.L.C.,
EASTMAN KODAK COMPANY**

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY12328:97443.11

PATENT
REEL: 010797 FRAME: 0487



SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contracts: Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employees
Schedule 6.1(c)	Consents

EXHIBIT A Warrant Agreement

*Schedule
1.1(c)
IP*

NY12328: 97443.11

-v-

REEL: 010797 FRAME: 0488

MAY 05 2000

SCHEDULE 1.1.e

<p>Novartis Systems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1999</p>			
Title of Invention	Country	Patent/Appn. No.	Status
Aerosols Containing Sclerosing Agents Nanoparticle Dispersions	U.S.	Patent No. 5,747,881	Granted
	Canada	Appn. No. 2,313,646	Pending
	Europe	Appn. No. 94963467.1	Pending
	Japan	Appn. No. E-323798	Pending
Aerosols Containing Nanoparticles Dispersions	U.S.	Patent No. 5,747,881	Granted
	Canada	Appn. No. 2,313,646	Pending
	Europe	Appn. No. 94963467.1	Pending
	Japan	Appn. No. E-323798	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulose Surface Stabilizers and Methods of Making Such Formulations	U.S.	Appn. No. 60/898,402	Pending
	ECT	ECT/0898/14087	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	U.S.	Patent No. 5,343,148	Granted
	U.S.	Patent No. 5,703,104	Granted
	Canada	Appn. No. 2,313,643	Pending
	Europe	Appn. No. 94867613.3	Pending
	Japan	Appn. No. E-323803	Pending
Nanoparticles Containing the R(-) Enantiomer of Desipramine	U.S.	Patent No. 5,718,919	Granted
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,385,106	Granted
Microencapsulation of Nanoparticles Pharmaceutical Agents	U.S.	Patent No. 5,365,832	Granted
Isolation of Ultra Small Particles	U.S.	Patent No. 5,303,723	Granted
Nanoparticles Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,643,132	Granted
Isolated Artery Mater	U.S.	Patent No. 5,473,683	Granted
	U.S.	Patent No. 5,373,749	Granted
	U.S.	Patent No. 5,323,679	Granted
	U.S.	Patent No. 5,466,433	Granted
Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,317,187	Granted
	Argentina	Appn. No. 326,106	Pending
	Australia	Patent No. 660832	Granted
	Canada	Appn. No. 2,107,400	Pending
	Taiwan	Patent No. N1-49476	Granted
	Czech	Appn. No. 93/2277	Pending
	Republic	Appn. No. 93/02793.6	Pending
	Europe	Patent/Appn. No. 934120	Pending
	Finland		

SCHEDULE 1.1.s

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/App. No.	Status
Method of Grinding Pharmaceutical Substances	Hungary	Patent No. 218022	Granted
	Japan	App. No. 282497/93	Pending
	South Korea	App. No. 22164/93	Pending
	Malaysia	Patent No. MY-108,418-A	Granted
	Mexico	App. No. 91-8443	Pending
	New Zealand	Patent No. 248111	Granted
	Norway	App. No. 83-28719	Pending
	Philippines	App. No. 81A7638	Pending
	Russia	Patent/App. No. 81/32896	Pending
	Slovak Republic	App. No. PV 1381/93	Pending
	Ukraine	App. No. 920368	Pending
	Venezuela	App. No. 146/93	Pending
Redispersible Nanoparticle Film Materials With Protective Overcoat	U.S.	Patent No. 5,971,783	Granted
	Canada	App. No. 2,212,103	Pending
	Europe	App. No. 8486412.7	Pending
	Japan	App. No. 8-328048	Pending
Isolated Argenine Compounds	U.S.	Patent No. 5,314,167	Granted
Method to Reduce Particle Size Growth During Lyophilization	U.S.	Patent No. 5,381,401	Granted
Isolated Benzoyl Acetate and Ketals for X-Ray Imaging	U.S.	Patent No. 5,336,739	Granted
Formulations of Compounds as Nanoparticle Dispersions in Digestible Oils or Fatty Acids	U.S.	Patent No. 5,371,556	Granted
	U.S.	Patent No. 5,340,811	Granted
	Canada	App. No. 2,307,304	Pending
	Europe	App. No. 94804332.5	Pending
	Japan	National Phase App. of PCT/US96/01433	Pending
Use of Non-Ionic Chelate Film Modifiers to Minimize Nanoparticle Aggregation During Sterilization	U.S.	Patent No. 5,348,762	Granted
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersant	U.S.	Patent No. 5,439,324	Granted
	Argentina	App. No. 328,135	Pending
	Australia	Patent No. 845648	Granted
	Canada	App. No. 2,104,192	Pending
	Taiwan	App. No. 81188768	Pending
	Europe	App. No. 93283343.7	Pending
	Finland	Pat/App. No. 83/2183	Pending
	Hungary	Pat/App. No. 8330394	Pending
	Israel	App. No. 93/107874	Pending
	Japan	App. No. 210799/93	Pending
	South Korea	App. No. 22706/93	Pending

SCHEDULE 1.1.e

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 28, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersion	Malaysia	Appln. No. PI 9302336	Granted
	New Zealand	Patent No. 248726	Granted
	Norway	Appln. No. 9834434	Pending
	Philippines	Patent No. 28037	Granted
	Russia	Appln. No. 93654841.80	Pending
	Slovak Republic	Appln. No. PV 1434-83	Pending
	Ukraine	Appln. No. 01603742	Pending
	U.K.	Patent No. 2,360,478	Granted
	Argentina	Appln. No. 134,528	Pending
	Australia	Patent No. 643443	Granted
Indicated Aryloxy Carbonamides	Canada	Appln. No. 2,187,387	Pending
	Taiwan	Patent No. 78-672317	Granted
	Hungary	Pat./Appln. No. P9501475	Hungary
	Israel	Appln. No. 93/107854	Granted
	Japan	Appln. No. 28091593	Pending
	South Korea	Appln. No. 93/21154	Pending
	Malaysia	Patent No. MY-188,303A	Granted
	New Zealand	Patent No. 248431	Granted
	Philippines	Patent No. 30136	Granted
	Ukraine	Appln. No. 0160468	Pending
	Venezuela	Patent No. 134495	Granted
	U.K.	Patent No. 2,431,393	Granted
	U.K.	Patent No. 2,511,767	Granted
	Europe	Appln. No. 92560132.4	Pending
	U.K.	Patent No. 2,152,439	Granted
X-Ray Contrast Compositions Useful in Medical Imaging			
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	Argentina	Appln. No. 134,528	Pending
	Taiwan	Appln. No. 82109713	Pending
	Japan	Appln. No. 28447283	Pending
	South Korea	Appln. No. 93/23383	Pending
	Malaysia	Appln. No. PI 9302336	Pending
	Mexico	Appln. No. 937381	Pending
	New Zealand	Patent No. 250116	Granted
	Philippines	Appln. No. 47231	Pending
	Russia	Appln. No. 93/53883	Pending
	Slovak Republic	Appln. No. PV 141683	Pending
	U.K.	Appln. No. 08/600,006	Pending
	U.K.	Patent No. 2,431,393	Granted
	U.K.	Patent No. 2,511,767	Granted
	Europe	Appln. No. 92560132.4	Pending
	U.K.	Patent No. 2,152,439	Granted
Formulations of Nanoparticulate Naproxen Tablets	U.K.	Appln. No. 08/600,006	Pending
	ECT	ECT/US94/03581	Pending

SCHEDULE 1.1.a

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Reduction of Intravenously Administered Nanoparticle Formulation Induced Adverse Physiological Reactions	U.S.	Appln. No. 08/694,754	Pending (Allowed)
	Canada	Based on PCT/US96/15300	Pending
	Europe	Based on PCT/US96/15300	Pending
	Japan	Based on PCT/US96/15300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles	U.S.	Patent No. 5,545,133	Granted
Burylene Oxide-Styrene Oxide Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	5,587,140	Granted
	Argentina	Appln. No. 332,343	Pending
	Australia	Appln. No. 28540/93	Pending
	Canada	Appln. No. 2,183,303	Pending
	Taiwan	Appln. No. 8406107531	Pending
	Europe	Appln. No. 8593888.0	Pending
	Finland	Pat/Appln. No. 843234	Pending
	Israel	Patent/Appln. No. 85/14354	Pending
	Japan	Appln. No. 503703/94	Pending
	Malaysia	Appln. No. PI 9301774	Pending
	Norway	Appln. No. P 943433	Pending
	Philippines	Appln. No. 38808	Pending
	Venezuela	Appln. No. 85/1028	Pending
Method of Grinding Pharmaceutical Substances	U.S.	Appln. No. 08/481,539	Pending (Allowed)
	Argentina	Appln. No. 331,838	Pending
	Canada	Appln. No. 2,190,948	Pending
	Taiwan	Appln. No. 84184440	Pending
	Europe	Appln. No. 85919218.4	Pending
	Israel	Appln. No. 85/115433	Allowed
	Japan	Appln. No. 538332/93	Pending
	Malaysia	Appln. No. PI 9301374	Pending
	Philippines	Appln. No. 50573	Pending
	Venezuela	Appln. No. 0833-93	Pending
Nanoparticle Diagnostic Devices as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,508,384	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,534,270	Granted
Solubilized Non-Ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,569,442	Granted
Iodinated Aromatic Propargylamine	U.S.	Patent No. 5,254,810	Granted
	U.S.	Patent No. 5,318,464	Granted
Iodinated Aryloxy Ketones	U.S.	Patent No. 5,418,123	Granted

SCHEDULE 1.1c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/Appln. No.	Status
Oral Purpose Diagnostic/Therapeutic Agent Containing a Tri-Iodinated Benzoyl Group Linked to a Coumarin	U.S.	Patent No. 5,645,330	Granted
Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,628,381	Granted
	U.S.	Appln. No. 00/813,346	Pending
Nanoparticulate Iodipamide Derivatives for Use as X-Ray Contrast Agents	U.S.	Patent No. 5,321,318	Granted
Nanoparticulate Diagnostic Diagnostic Agent X-Ray Contrast Agents for Blood Pool and Therapeutic System Imaging	U.S.	Patent No. 5,325,328	Granted
Polymers and Anticorrosive Stabilizers	U.S.	Patent No. 5,393,637	Granted
Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents	U.S.	Patent No. 5,481,482	Granted
Novel Formulation for Nanoparticulate X- Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic Surfactants	U.S.	Patent No. 5,324,332	Granted
	U.S.	Patent No. 5,447,710	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Patent No. 5,388,262	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,476,583	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,318,118	Granted
Nanoparticulate NSAID Formulations	U.S.	Patent No. 5,318,738	Granted
	Canada	Appln. No. 2,312,779	Pending
	Europe	Appln. No. 9695181.2 (to be completed in all EP designated countries)	Pending (Allowed)
	Japan	Appln. No. 8-324348	Pending
	U.S.	Patent No. 5,568,932	Granted
Microprecipitation of Nanoparticulate Pharmaceutical Agents	U.S.	Patent No. 5,716,643	Granted
Microprecipitation of Nanoparticulate Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,643,331	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,642,883	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,143,684	Granted
Surface Modified Drug Nanoparticles	Argentina	Appln. No. 92/521681	Pending

SCHEDULE 1.1.a

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Drug Nanoparticles	Australia	Patent No. 634834	Granted
	Canada	Appn. No. 2859433	Pending
	Chile	Appn. No. 82074	Pending
	Columbia	Patent No. 3443	Granted
	Europe	Appn. No. 9228131.1 Publication No. 499299	Pending
	Finland	Pat/Appn. No. 88831	Pending
	Hungary	Pat/Appn. No. 85-216	Pending
	Ireland	Appn. No. 83-0217	Pending
	Israel	Patent/Appn. No. 105734	Granted
	Japan	Appn. No. 83/1228	Pending
	South Korea	Appn. No. 83/1877	Pending
	Malaysia	Patent No. MY-108134-A	Granted
	Mexico	Patent No. 178343	Granted
	New Zealand	Patent No. 241342	Granted
	Norway	Appn. No. 82-08134	Allowed
	Philippines	Patent No. 29049	Granted
	Russia	Pat. No. 258133	Granted
	Singapore	Appn. No. 860341-3	Pending
	Taiwan	Patent No. NI-871313	Granted
Surface Modified Anticancer Nanoparticles	U.K.	Patent No. 2,484,281	Granted
	U.S.	Patent No. 5,885,345	Granted
	Argentina	Appn. No. 83/023,338	Pending
	Australia	Patent No. 875432	Granted
	Canada	Appn. No. 2859433	Pending
	Czech Republic	Appn. No. PV 131293	Pending
	China	Appn. No. 8310850.9	Pending
	Europe	Appn. No. 9328188.1 Publication No. 577215	Pending
	Finland	Pat/Appn. No. 833405	Pending
	Hungary	Pat/Appn. No. 83301917	Pending
	Israel	Patent/Appn. No. 108134	Pending
	Japan	Appn. No. 83/13888	Pending
	South Korea	Appn. No. 83/12247	Pending
	Malaysia	Appn. No. PI 830133	Pending (allowed)
	Mexico	Appn. No. 931830	Pending
	New Zealand	Patent No. 248042	Granted
	Norway	Appn. No. 83-3405	Pending
	Philippines	Patent No. 30184	Granted
	Russia	Appn. No. 93046236	Pending
	Singapore	Appn. No. 8603403-6	Pending
	Slovak Republic	Pat/Appn. No. PV 0681-83	Pending
	Taiwan	Patent No. NI-875234	Granted
	Ukraine	Appn. No. 9300957	Pending

Issued and Granted Patents
August 20, 1958

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles Surface Modified NEAD Nanoparticles	Venezuela	Pat/Appn. No. 6148-81	Pending
	U.S.	Patent No. 3,352,168	Granted
	Australia	Patent No. 677783	Granted
	Austria	European Patent No. 644 735	National Registration of EP 644 735
	Belgium	European Patent No. 644 735	National Registration of EP 644 735
	Canada	Appn. No. 3118317	Pending
	Denmark	European Patent No. 644 735	National Registration of EP 644 735
	Europe	European Patent No. 644 735	Granted
	France	European Patent No. 644 735	National Registration of EP 644 735
	Germany	European Patent No. 644 735	National Registration of EP 644 735
	Greece	European Patent No. 644 735	National Registration of EP 644 735
	Hungary	Pat/Appn. No. 54-3543	Pending
	Ireland	European Patent No. 644 735 Irish Patent No. 1072003	Granted
	Italy	European Patent No. 644 735	National Registration of EP 644 735
	Japan	Appn. No. 54/501313	Pending
	Luxembourg	European Patent No. 644 735	National Registration of EP 644 735
	Monaco	European Patent No. 644 735	National Registration of EP 644 735
	Mexico	Appn. No. 53-3433	Pending
	Netherlands	European Patent No. 644 735	National Registration of EP 644 735
	Portugal	European Patent No. 644 735	National Registration of EP 644 735
	Spain	European Patent No. 644 735	National Registration of EP 644 735

**NovoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 28, 1998**

Title of Invention	Country	Patent/Appn. No.	Status
Multi-Functional NSAID Nanoparticles	Sweden	European Patent No. 644 733	National Registration of EP 644 733
	Switzerland	European Patent No. 644 733	Granted
	United Kingdom	European Patent No. 644 733	National Registration of EP 644 733
Controlled Adhesion Within the GI-Tract of Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene oxide) Polymers	U.S.	Patent No. 5,388,379	Granted
Controlled Imaging X-Ray Contrast Agents	U.S.	Patent No. 5,371,750	Granted
Controlled Surface for Nanoparticles	U.S.	Patent No. 5,433,938	Granted
Encapsulations of Oral Gastrointestinal Soluble X-Ray Contrast Agents in Emulsion with Pharmaceutically Compatible Clays	U.S.	Patent No. 5,444,440	Granted
Novel Nanoparticles with Hydroxypropyl Cellulose as a Dispersion Stabilizer	U.S.	Patent No. 5,581,436	Granted
Novel 2,4,6-Trisubstituted-Amino- Phenols as X-Ray Contrast Agents	U.S.	Patent No. 5,678,136	Granted
Novel (Amino)-2,4,6- Trisubstituted Esters	U.S.	Patent No. 5,603,916	Granted
Novel Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,718,308	Granted
	Argentina	Appn. No. 331,837	Pending
	Canada	Appn. No. 2,196,134	Pending
	Taiwan	Appn. No. 84163643	Pending
	Europe	Appn. No. 93919081.6	Pending
	Israel	Appn. No. 113831	Pending
	Japan	Appn. No. 93/030317	Pending
	Malaysia	Appn. No. P19301375	Pending
	Philippines	Appn. No. 93/06374	Pending
	Venezuela	Appn. No. 6854-93	Pending
Alkylphenol Esters as Novel X-Ray Contrast Agents	U.S.	Appn. No. 08/677,768	Pending
Novel 2,4,6-Trisubstituted Esters as X- Ray Contrast Agents	U.S.	Patent No. 5,648,146	Granted September 16, 1997
Novel Copolymers and a Process for Preparing Them	U.S.	Appn. No. 08/036,819	Pending
	Argentina	Appn. No. 331,135	Pending
	Canada	Appn. No. 2,207,349	Pending
	Taiwan	Appn. No. 8406102782	Pending
	Europe	Appn. No. 93/043261.4	Pending
	Israel	Appn. No. 84/012136	Pending

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
Block Copolymers and a Process for Making Them	Europe	National Phase of PCT/EP94/04261	Pending
	Japan	National Phase of PCT/EP94/04261	Pending
	Malaysia	Appln. No. PI 950852	Pending
	Monaco	Appln. No. 951193	Pending
	Philippines	Appln. No. 98338	Pending
	Great Britain	Patent No. 2283977	Granted
	Venezuela	Appln. No. 93/114	Pending
Rhombohedral Crystalline Form of Trans-1,2-Dichloroethane Acetate, Compositions Incorporating the Rhombohedral Crystalline Form of Trans-1,2-Dichloroethane Acetate, Methods of Making and Using Such Compositions, Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Trans-1,2-Dichloroethane Acetate	U.S.	Appln. No. 08/941,281	Pending
Formulations of Naproxen	U.S.	Appln. No. Unknown (filed on August 13, 1998)	Pending



the Acquired Assets are subject, other than in the case of clauses (II) and (III) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

4.4 Binding Effect. This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

4.5 Consents and Approvals. Except as required by the H-S-R Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

4.6 Intellectual Property. To the best knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(e) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

NY12522: 97443.11

-17-

Property to any Person All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

4.7 Title to and Condition of Tangible Property. Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except (i) Leases for Taxes, assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

4.8 Contracts

(a) Schedule 4.8(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.8(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

-18-

NY12328 97443 11

Received 04-22-88 11:05am

From-

To: FOLEY AND LARSON
PATENT
Page 04
REEL: 010797 FRAME: 0499

**ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PACLITAXEL**

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Eastman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby ASSIGNS to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particulate Prospects Corp.,
Member

By: [Signature]
Name: Akram Sandhu
Title: Vice President

NY12523-1998203

Received 04-22-00 11:05am
RECORDED: 05/05/2000

From

To-FOLEY AND BROWNE Page 08
PATENT
REEL: 010797 FRAME: 0500

EXHIBIT 6

Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2

Patent #: 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS

Assignment: 1

Reel/Frame: 010797/0486

Recorded: 05/05/2000

Pages: 15

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: NANOSYSTEMS, L.L.C.

Exec Dt: 10/01/1998

Assignee: ELAN CORPORATION, PLC
LINCOLN HOUSE, LINCOLN PLACE
DUBLIN 2, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8696

Assignment: 2

Reel/Frame: 010797/0501

Recorded: 05/05/2000

Pages: 17

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ELAN CORPORATION, PLC

Exec Dt: 10/01/1998

Assignee: ELAN PHARMA INTERNATIONAL LIMITED
WIL HOUSE, SHANNON BUSINESS PARK
SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-8696

FORM PTO-1585 (modified)
(Rev. 8-83)

RECO

05-23-2000



EET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

5.5.00

101384078

To the Commissioner of Patents and Trademarks: Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

Elan Corporation, PLC



2. Name and address of receiving party(ies):

Elan Pharma International Limited
WIL House, Shannon Business Park
Shannon, Co. Clare
IRELAND

Additional conveying party(ies)

NO

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer
FOLLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
P.O. Box 25696
Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

☒ Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05/23/2000 JMM:Z 0000073 00540216

DO NOT USE THIS SPACE

01 FC:501

40.00

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

May 5, 2000

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 17

ASSIGNMENT AGREEMENT

ASSIGNMENT AGREEMENT among Elan Corporation, plc ("Elan") and Elan Pharma International Limited, a wholly-owned subsidiary of Elan ("EPIL"). For consideration consisting of an amount in cash equal to the Purchase Price (as defined in the Agreement) less the sum of the amounts paid by Elan Pharmaceutical Research Corp. ("ELRC") to Elan in consideration for the assets separately conveyed plus the amounts paid by EPIL to Nanosystems I.L.C. for certain household improvements, the parties hereto agree that, effective immediately after the closing of the transactions referred to in the Agreement referred to below, Elan assigns to EPIL all of Elan's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Asset Purchase Agreement (the "Agreement") by and among Nanosystems I.L.C., Eastman Kodak Company and Elan.


Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.

[Signature page follows]

-2-

IN WITNESS WHEREOF, the parties hereto have executed
 this Assignment Agreement as of the 1st day of October, 1998.

ELAN CORPORATION, PLC

By: 
 Name: Donald Stanley
 Title: Chairman of Board
 Director of Elan Corp., pl.

We hereby assume the rights, title and interest specified
 above.

ELAN PHARMACEUTICALS
 LIMITED

By: 
 Name: David H. H. H.
 Title: Director



ASSET PURCHASE AGREEMENT

by and between

**NANOSYSTEMS L.L.C.,
EASTMAN KODAK COMPANY**

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY12328 97443.11

PATENT

REEL: 010797 FRAME: 0504



SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contract Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employee
Schedule 6.1(c)	Consents

EXHIBIT A Warrant Agreement

*Schedule
1.1(c)
IP*

NY 12328: 97443.11

REEL: 010797 FRAME: 0505

SCHEDULE 1.1.e

MAY 05 2000

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**

August 20, 1998

Title of Invention	Country	Patent/Appln. No.	Status
Aerosols Containing Neomycinase Nanoparticle Dispersions	U.S.	Patent No. 5,747,801	Granted
	Canada	Appln. No. 2,313,660	Pending
	Europe	Appln. No. 94804367.1	Pending
	Japan	Appln. No. E-323798	Pending
Aerosols Containing Neomycinase Nanoparticle Dispersions	U.S.	Appln. No. 6,054,113.18	Pending
	Canada	Appln. No. 2,313,634	Pending
	Europe	Appln. No. 94804366.3	Pending
	Japan	Appln. No. E-323798	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulose Surfaces Stabilizers and Methods of Making Such Formulations	U.S.	Appln. No. 6,078,602	Pending
	ECT	ECT/00898/14057	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	U.S.	Patent No. 5,343,128	Granted
	U.S.	Patent No. 5,705,194	Granted
	Canada	Appln. No. 2,313,643	Pending
	Europe	Appln. No. 94807813.3	Pending
Nanoparticles Containing the R(-) Enantiomer of Ibuprofen	Japan	Appln. No. E-323863	Pending
	U.S.	Patent No. 5,718,918	Granted
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,343,108	Granted
Microencapsulation of Nanoparticle Pharmaceutical Agents	U.S.	Patent No. 5,340,932	Granted
Isolation of Ultra Small Particles	U.S.	Patent No. 5,303,723	Granted
Nanoparticle Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,643,332	Granted
	U.S.	Patent No. 5,472,643	Granted
	U.S.	Patent No. 5,373,749	Granted
	U.S.	Patent No. 5,322,679	Granted
Indinavir Acrylamide Esters	U.S.	Patent No. 5,464,433	Granted
	U.S.	Patent No. 5,318,187	Granted
Method of Grinding Pharmaceutical Substances	Argentina	Appln. No. 326,266	Pending
	Australia	Patent No. 640832	Granted
	Canada	Appln. No. 2,187,400	Pending
	Taiwan	Patent No. NT-48476	Granted
	China	Appln. No. 93/2377	Pending
	Republic Europe	Appln. No. 93202795.6	Pending
	Finland	Patent/Appln. No. 934320	Pending

PATENT

REEL: 010797 FRAME: 0506

SCHEDULE 1.1.1

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 30, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
Method of Grinding Pharmaceutical Substances	Hungary	Patent No. 318321	Granted
	Japan	Appln. No. 212497/93	Pending
	South Korea	Appln. No. 22264/93	Pending
	Malaysia	Patent No. MY-108,411-A	Granted
	Mexico	Appln. No. 93-8443	Pending
	New Zealand	Patent No. 242813	Granted
	Norway	Appln. No. 85-28719	Pending
	Philippines	Appln. No. 8147259	Pending
	Russia	Patent/Appln. No. 21/52286	Pending
	Slovak Republic	Appln. No. PV 1301/93	Pending
	Ukraine	Appln. No. 932408	Pending
	Venezuela	Appln. No. 1484/93	Pending
	U.K.	Patent No. 2,373,713	Granted
Redispersible Nanoparticulate Film Membranes With Protective Overcoats	Canada	Appln. No. 2,312,853	Pending
	Europe	Appln. No. 94004412.7	Pending
	Japan	Appln. No. 8-325846	Pending
	U.K.	Patent No. 2,384,187	Granted
Initiated Aromatic Compounds	U.K.	Patent No. 2,382,401	Granted
Method to Reduce Particle Size Growth During Lyophilization	U.K.	Patent No. 2,338,798	Granted
Initiated Benzoyl Acetals and Ketals for X-Ray Imaging	U.K.	Patent No. 2,371,556	Granted
Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids	U.K.	Patent No. 2,346,351	Granted
	Canada	Appln. No. 2,307,304	Pending
	Europe	Appln. No. 94001332.3	Pending
	Japan	National Phase Appln. of PCT/US94/01433	Pending
	U.K.	Patent No. 2,346,782	Granted
Use of Non-Ionic Chelate Film Modifiers to Minimize Nanoparticulate Aggregation During Sterilization	U.K.	Patent No. 2,429,324	Granted
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersant	U.K.	Patent No. 2,429,324	Granted
	Argentina	Appln. No. 934,178	Pending
	Australia	Patent No. 663449	Granted
	Canada	Appln. No. 2,168,192	Pending
	Taiwan	Appln. No. 82108788	Pending
	Europe	Appln. No. 93283342.7	Pending
	Finland	Pat./Appln. No. 8103383	Pending
	Hungary	Pat./Appln. No. 93361394	Pending
	Israel	Appln. No. 92/187674	Pending
	Japan	Appln. No. 218094/93	Pending
	South Korea	Appln. No. 22705/93	Pending

SCHEDULE 1.1.2

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998

Title of Invention	Country	Patent/Appln. No.	Status
The Use of Tylomopal as a Nanoparticle Stabilizer and Dispersant	Malaysia	Appln. No. PI 9302634	Granted
	New Zealand	Patent No. 248726	Granted
	Norway	Appln. No. P934434	Pending
	Philippines	Patent No. 29837	Granted
	Russia	Appln. No. 93054941.00	Pending
	Slovak Republic	Appln. No. PV 1424-93	Pending
	Ukraine	Appln. No. 93003742	Pending
	U.K.	Patent No. 2,300,478	Granted
	Argentina	Appln. No. 326,629	Pending
	Australia	Patent No. 643443	Granted
Iodinated Aryloxy Carbonamides	Canada	Appln. No. 2,107,307	Pending
	Taiwan	Patent No. NI-972317	Granted
	Hungary	Pat./Appln. No. P9303475	Pending
	Israel	Appln. No. 93/107034	Granted
	Japan	Appln. No. 28091503	Pending
	South Korea	Appln. No. 93/21134	Pending
	Malaysia	Patent No. MY-108,203A	Granted
	New Zealand	Patent No. 248431	Granted
	Philippines	Patent No. 30136	Granted
	Ukraine	Appln. No. 93/0409	Pending
	Venezuela	Patent No. 1334/93	Granted
	U.K.	Patent No. 2,431,393	Granted
	U.K.	Patent No. 2,518,767	Granted
X-Ray Contrast Compositions Useful in Medical Imaging	Europe	Appln. No. 92200132.4	Pending
	U.K.	Patent No. 2,322,459	Granted
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	Argentina	Appln. No. 326,529	Pending
	Taiwan	Appln. No. 82109723	Pending
	Japan	Appln. No. 216672/93	Pending
	South Korea	Appln. No. 93/21383	Pending
	Malaysia	Appln. No. PI 9302339	Pending
	Mexico	Appln. No. 937381	Pending
	New Zealand	Patent No. 250116	Granted
	Philippines	Appln. No. 47231	Pending
	Russia	Appln. No. 93/15883	Pending
	Slovak Republic	Appln. No. PV 1416/93	Pending
	U.K.	Appln. No. 02/800,006	Pending
	PCT	PCT/US98/03388	Pending
Formulations of Nanoparticulate Naproxen Tablets			

SCHEDULE 1.1.a

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Reduction of Intravenously Administered Nanoparticle Formulation Induced Adverse Physiological Reactions	U.S.	Appln. No. 08/494,734	Pending (Allowed)
	Canada	Based on PCT/US96/13300	Pending
	Europe	Based on PCT/US96/13300	Pending
	Japan	Based on PCT/US96/13300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles	U.S.	Patent No. 5,343,133	Granted
Biodegradable Polymeric Cores with Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	5,307,143	Granted
	Argentina	Appln. No. 132,233	Pending
	Australia	Appln. No. 28340/93	Pending
	Canada	Appln. No. 2,183,503	Pending
	Taiwan	Appln. No. 8408167331	Pending
	Europe	Appln. No. 93823882.6	Pending
	Finland	Pat/Appln. No. 945214	Pending
	Israel	Patent/Appln. No. 93/14234	Pending
	Japan	Appln. No. 301303/94	Pending
	Malaysia	Appln. No. P19301774	Pending
	Norway	Appln. No. P 943433	Pending
	Philippines	Appln. No. 30809	Pending
	Venezuela	Appln. No. 83/1624	Pending
	U.S.	Appln. No. 08/491,319	Pending (Allowed)
Method of Grinding Pharmaceutical Substances	Argentina	Appln. No. 311,931	Pending
	Canada	Appln. No. 2,190,348	Pending
	Taiwan	Appln. No. 84184448	Pending
	Europe	Appln. No. 93813823.1	Pending
	Israel	Appln. No. 93/113833	Allowed
	Japan	Appln. No. 316333/93	Pending
	Malaysia	Appln. No. P19301374	Pending
	Philippines	Appln. No. 30373	Pending
	Venezuela	Appln. No. 0833-85	Pending
Nanoparticle Diagnostic Dimer as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,300,304	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,334,978	Granted
Stable Non-Ionic Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,369,441	Granted
Iodinated Aromatic Propagations	U.S.	Patent No. 5,244,610	Granted
	U.S.	Patent No. 5,322,404	Granted
Iodinated Aromatic Kinases	U.S.	Patent No. 5,418,113	Granted

SCHEDULE 1.1:

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Oral Purpose Diagnostic/Therapeutic Agent Containing a Tri-Iodinated Benzoyl Group Linked to a Carbohydrate	U.S.	Patent No. 5,665,330	Granted
Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,621,981	Granted
Nanoparticles in Iodipamide Derivatives for Use as X-Ray Contrast Agents	U.S.	Appn. No. 08/819,348	Pending
	U.S.	Patent No. 5,521,318	Granted
Nanoparticles Diagnostic Diagnostic Enzyme X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,523,328	Granted
Various Salt Formulations Stabilized by Non-Ionic and Anionic Stabilizers	U.S.	Patent No. 5,583,637	Granted
Water Insoluble Non-Magnetic Manganese Complexes as Magnetic Resonance Contrast Agents	U.S.	Patent No. 5,481,422	Granted
Novel Formulations for Nanoparticle X- Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic Surfactants	U.S.	Patent No. 5,534,552	Granted
	U.S.	Patent No. 5,447,718	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Lyophilization	U.S.	Patent No. 5,388,562	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,476,583	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,310,318	Granted
Nanoparticle NEAD Formulations	U.S.	Patent No. 5,518,738	Granted
	Canada	Appn. No. 2,312,779	Pending
	Europe	Appn. No. 9805181.2 (to be completed in all EP designated countries)	Pending (Allowed)
	Japan	Appn. No. 8-334248	Pending
Microprecipitation of Nanoparticle Pharmaceutical Agents	U.S.	Patent No. 5,540,812	Granted
Microprecipitation of Nanoparticle Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,714,642	Granted
Co-Microprecipitation of Nanoparticle Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,643,331	Granted
Co-Microprecipitation of Nanoparticle Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,642,125	Granted
Surface Modified Drug Nanoparticles	U.S.	Patent No. 5,143,654	Granted
	Argentina	Appn. No. 92/321681	Pending

SCHEDULE 1.1.2

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Drug Nanoparticles	Australia	Patent No. 634836	Granted
	Canada	Appn. No. 2859433	Pending
	China	Appn. No. 92874	Pending
	Columbia	Patent No. 34613	Granted
	Europe	Appn. No. 92881312 Publication No. 496299	Pending
	Finland	Pat/Appn. No. 830531	Pending
	Hungary	Pat/Appn. No. 81-228	Pending
	Ireland	Appn. No. 92-0217	Pending
	Israel	Patent/Appn. No. 108754	Granted
	Japan	Appn. No. 92/11228	Pending
	South Korea	Appn. No. 92/1077	Pending
	Malaysia	Patent No. MY-108134-A	Granted
	Mexico	Patent No. 176343	Granted
	New Zealand	Patent No. 341562	Granted
	Norway	Appn. No. 92-00334	Allowed
	Philippines	Patent No. 29089	Granted
	Russia	Pat. No. 2084333	Granted
	Singapore	Appn. No. 920331-J	Pending
	Taiwan	Patent No. NI-071312	Granted
Surface Modified Anticancer Nanoparticles	U.S.	Patent No. 5,484,683	Granted
	U.S.	Patent No. 5,398,363	Granted
	Argentina	Appn. No. 92/333,020	Pending
	Australia	Patent No. 675432	Granted
	Canada	Appn. No. 2886342	Pending
	Czech Republic	Appn. No. PV 131693	Pending
	China	Appn. No. 93108834.9	Pending
	Europe	Appn. No. 93261881.1 Publication No. 577215	Pending
	Finland	Pat/Appn. No. 933045	Pending
	Hungary	Pat/Appn. No. P8301917	Pending
	Israel	Patent/Appn. No. 108198	Pending
	Japan	Appn. No. 93/13888	Pending
	South Korea	Appn. No. 92/13247	Pending
	Malaysia	Appn. No. PI 9301273	Pending (allowed)
	Mexico	Appn. No. 923930	Pending
	New Zealand	Patent No. 348042	Granted
	Norway	Appn. No. 92-2403	Pending
	Philippines	Patent No. 30104	Granted
	Russia	Appn. No. 93046256	Pending
	Singapore	Appn. No. 9405405-6	Pending
	Slovak Republic	Pat/Appn. No. PV 0681-93	Pending
	Taiwan	Patent No. NI-679234	Granted
	Ukraine	Appn. No. 93000637	Pending

Issued and Granted Patents
August 28, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles Surface Modified NSAID Nanoparticles	Venezuela	Pat/Appn. No. 0848-83	Pending
	U.K.	Patent No. 3,332,128	Granted
	Australia	Patent No. 677783	Granted
	Austria	European Patent No. 644 735	National Registration of EP 644 735
	Belgium	European Patent No. 644 735	National Registration of EP 644 735
	Canada	Appn. No. 3118317	Pending
	Denmark	European Patent No. 644 735	National Registration of EP 644 735
	Europe	European Patent No. 644 735	Granted
	France	European Patent No. 644 735	National Registration of EP 644 735
	Germany	European Patent No. 644 735	National Registration of EP 644 735
	Greece	European Patent No. 644 735	National Registration of EP 644 735
	Hungary	Pat/Appn. No. 84-1343	Pending
	Ireland	European Patent No. 644 735 Irish Patent No. 1172603	Granted
	Italy	European Patent No. 644 735	National Registration of EP 644 735
	Japan	Appn. No. 94/301313	Pending
	Luxembourg	European Patent No. 644 735	National Registration of EP 644 735
	Monaco	European Patent No. 644 735	National Registration of EP 644 735
	Mexico	Appn. No. 93-3432	Pending
	Netherlands	European Patent No. 644 735	National Registration of EP 644 735
	Portugal	European Patent No. 644 735	National Registration of EP 644 735
	Spain	European Patent No. 644 735	National Registration of EP 644 735

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appn. No.	Status
Modified NSAID Nanoparticles	Sweden	European Patent No. 644 733	National Registration of EP 644 733
	Switzerland	European Patent No. 644 733	Granted
	United Kingdom	European Patent No. 644 733	National Registration of EP 644 733
Enhancing the Adhesion Within the GI-Tract of Nanoparticles Substituted by High Molecular Weight, Linear Poly(ethylene Glycol) Polymers	U.S.	Patent No. 5,380,375	Granted
Enhanced Imaging X-Ray Contrast Agents	U.S.	Patent No. 5,378,730	Granted
Enhanced Substrates for Nanocrystals	U.S.	Patent No. 5,332,978	Granted
Formulations of Oral Gastrointestinal Contrast X-Ray Contrast Agents in Combination with Pharmacologically Active Clays	U.S.	Patent No. 5,468,440	Granted
Formulation of Naproxen with Hydroxypropyl Cellulose as a Dispersion Substituting	U.S.	Patent No. 5,391,436	Granted
Formulation of 3-Substituted-Amino-Phthalate Esters Useful as X-Ray Contrast Agents for Medical Diagnostic	U.S.	Patent No. 5,470,136	Granted
Formulation of (A Mannyl Amino)-3,4,6-Trimethylphenyl Esters	U.S.	Patent No. 5,468,916	Granted
Formulation of Grindings of Pharmaceutical Substances	U.S.	Patent No. 5,718,388	Granted
	Argentina	Appn. No. 331,937	Pending
	Canada	Appn. No. 2,195,134	Pending
	Taiwan	Appn. No. 84181642	Pending
	Europe	Appn. No. 93919682.5	Pending
	Israel	Appn. No. 112851	Pending
	Japan	Appn. No. 93530317	Pending
	Malaysia	Appn. No. P1 9301375	Pending
	Philippines	Appn. No. 9350574	Pending
	Venezuela	Appn. No. 0834-93	Pending
	U.S.	Appn. No. 08/777,708	Pending
Formulation of Novel X-Ray Contrast Agents	U.S.	Patent No. 5,441,166	Granted September 16, 1997
Formulation of Novel 3-Amino-Trimethylphenyl Esters as X-Ray Contrast Agents	U.S.	Appn. No. 08/834,810	Pending
	Argentina	Appn. No. 331,133	Pending
	Canada	Appn. No. 2,287,369	Pending
	Taiwan	Appn. No. 8408162792	Pending
	Europe	Appn. No. 93063364	Pending
	Israel	Appn. No. 940112136	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Copolyesters and a Process for Making Them	Europe	National Phase of PCT/EP94/04261	Pending
	Japan	National Phase of PCT/JP94/04261	Pending
	Malaysia	Appn. No. P1930052	Pending
	Mexico	Appn. No. 951135	Pending
	Philippines	Appn. No. 90138	Pending
	Greece	Patent No. 228377	Granted
	Britain		
Rhombohedral Crystalline Form of Transcinnolene Acetonide, Compositions Involving the Rhombohedral Crystalline Form of Transcinnolene Acetonide, Methods of Making and Using Such Compositions, and Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Transcinnolene Acetonide Stable Formulations of Naproxen	Venezuela	Appn. No. 93/034	Pending
	U.S.	Appn. No. 08/943,281	Pending
	U.S.	Appn. No. Unknown (filed on August 13, 1998)	Pending

the Acquired Assets are subject, other than in the case of clauses (ii) and (iii) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

4.4 Binding Effect. This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

4.5 Consents and Approvals. Except as required by the H-S-R Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

4.6 Intellectual Property. To the best knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(e) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

-17-

NY12532: 97443.11

Property to any Person. All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

4.7 Title to and Condition of Tangible Property. Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except (i) Liens for Taxes, assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

4.8 Contracts.

(a) Schedule 4.2(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.2(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

NY12328: 97443 11

-18-

ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PACIFIC FAXEL

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Eastman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby ASSIGNS to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of PacificFaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particulate Prospects Corp.,
Member

By: M. S. Sandhu

Name: Akram Sandhu
Title: Vice President

NY12525-199120 1

RECORDED: 06/06/2000

From-

To-FOLEY AND LARSONER
PATENT

Page 03

REEL: 010797 FRAME: 0517

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.